Main Products/ Services/ Pipelines & Platforms
MAIN PRODUCTS (MINC Platform technology) Suntec is a clinical stage biopharmaceutical company with MINC (Multi-target Immune-modulation Nanocomplex) platform. MINC generates first in class NME/NCE with high efficacy and safety. Three products are ready for out-licensing/collaboration discussions. STM-001 • Indications: Glioma (plus 5 other Cancers) • Stage: Phase 1 (at M.D. Andersons, Johns Hopkins, Northwestern). • Received NIH award as “The most promising cancer drugs” STM-003 • Indications: Liver cancer (plus immunotherapy to overcome resistance to anti-PD-(L)1) • Stage: IND ready (6/2025) • In collaboration with Dr. T. Honjo, 2018 Nobel laureate. STM-002 • Indications: Alzheimer's (plus Parkinson’s, Multiple sclerosis) • Stage: IND ready (12/2024) • Interests from ADDF and several major pharmaceutical companies * All three drugs expect FDA “Breakthrough Designations” with 18 yr IP protections
Business Interests
Initiate the business discussions for STM-001, 002, 003 licensing or collaborations (product handover after receiving FDA “breakthrough” designations).
Contact Info
Isaac Cheng
VP Research
+1 909-713-7187
isaac.cheng@suntecmedical.com